This week's roundup of Houston innovators includes Craig Ceccanti of T-Minus Solutions, Ben Jawdat of Revterra, and Sam Sabbahi of Thermocuff. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from software development to medical devices — recently making headlines in Houston innovation.

Craig Ceccanti, founder of T-Minus Solutions

Craig Ceccanti joins the Houston Innovators Podcast to share what he's learned in his time as an entrepreneur in Houston — and what he's focused on now. Photo courtesy of Craig Ceccanti

When deciding what his passion project would be, Craig Ceccanti looked back at his career. He's always been interested in tech, and grew a small business — Pinot's Palette — to a national franchise. Combining his skills and expertise, he founded T-Minus Solutions to provide entrepreneurs with software consulting and support.

"I love technology and mentoring other entrepreneurs — those were two big factors," Ceccanti says on the Houston Innovators Podcast. "So, starting a consulting agency where we could help startups and mid sized-growth companies build custom software was kind of my perfect unicorn."

He shares more about the his career — from franchising to tech startups — as well as why he's bullish on Houston's business economy on the podcast. Click here to read more and listen to the episode.

Ben Jawdat, CEO and founder of Revterra

Revterra Corp. closed a $6 million series A round led by Equinor Ventures. Photo via LinkedIn

Revterra Corp. has raised $6 million in its series A funding round to propel development of its battery for electric vehicle charging stations. Norway’s Equinor Ventures led the round, with participation from Houston-based SCF Ventures. Previously, Revterra raised nearly $500,000 through a combination of angel investments and a National Science Foundation grant.

“There is an urgent need to reduce carbon emissions globally,” physicist Ben Jawdat, founder and CEO of Revterra, says in a news release. “Our goal at Revterra is to deploy scalable energy storage solutions that facilitate the shift to renewables and EVs while hardening our electric grid. Our systems enable these ambitions while utilizing materials that are recyclable and based on a secure supply chain.” Click here to read more.

Thermocuff has several patents and expects FDA approval at the end of the year. Image via LinkedIn.com

Necessity is the mother of invention — and Sam Sabbahi needed a better way to heat and cool common joint injuries. Sabbahi, a physical therapist by trade, wanted to optimize the traditional way of using ice or heat packs.

“In the field, we were always getting people coming in trying to get us to purchase different medical devices and we wondered, ‘who knows what we need better than we do?’” he says. “A patient asked me ‘what a cold pack does’ and I was thinking in my head that a cold pack just cools the skin to three millimeters depth.”

Sabbahi then developed and invented a portable convection-based heating and cooling system device that could be used for joint injury rehabilitation – the device, dubbed Thermocuff, works much in the way that an air fryer circulates the air to get an even temperature. Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.